

Edited by
Fabrizio Giordanetto

Early Drug Development

Bringing a Preclinical Candidate to the Clinic

Volume 73

Series Editors:
R. Mannhold, H. Buschmann,
J. Holenz



Early Drug Development

Methods and Principles in Medicinal Chemistry

Edited by Raimund Mannhold, Helmut Buschmann, Jörg Holenz
G. Folkers, H. Kubinyi, H. Timmerman, H. van de Waterbeemd, J. Bondo Hansen

Previous Volumes of this Series:

Handler, N. and Buschmann, H. (Eds.)

Drug Selectivity

An Evolving Concept in Medicinal Chemistry

2018
ISBN: 978-3-527-33538-1
Vol. 72

Erlanson, D. A. and Jahnke, W. (Eds.)

Fragment-based Drug Discovery

Lessons and Outlook

2015
ISBN: 978-3-527-33775-0
Vol. 67

Vaughan, T., Osbourn, J., and Jalla, B. (Eds.)

Protein Therapeutics

2017
ISBN: 978-3-527-34086-6
Vol. 71

Urbán, L., Patel, V. F., and Vaz, R. J. (Eds.)

Antitargets and Drug Safety

2015
ISBN: 978-3-527-33511-4
Vol. 66

Ecker, G. F., Clausen, R. P., and Sitte, H. H. (Eds.)

Transporters as Drug Targets

2017
ISBN: 978-3-527-33384-4
Vol. 70

Keserü, G. M. and Swinney, D. C. (Eds.)

Kinetics and Thermodynamics of Drug Binding

2015
ISBN: 978-3-527-33582-4
Vol. 65

Martic-Kehl, M. I. and Schubiger, P.A. (Eds.)

Animal Models for Human Cancer

Discovery and Development of Novel Therapeutics

2017
ISBN: 978-3-527-33997-6
Vol. 69

Pfannkuch, F. and Suter-Dick, L. (Eds.)

Predictive Toxicology

From Vision to Reality

2014
ISBN: 978-3-527-33608-1
Vol. 64

Holenz, Jörg (Ed.)

Lead Generation

Methods and Strategies

2016
ISBN: 978-3-527-33329-5
Vol. 68

Kirchmair, J. (Ed.)

Drug Metabolism Prediction

2014
ISBN: 978-3-527-33566-4
Vol. 63

Early Drug Development

Bringing a Preclinical Candidate to the Clinic

Edited by Fabrizio Giordanetto

Volume 1

WILEY-VCH

Early Drug Development

Bringing a Preclinical Candidate to the Clinic

Edited by Fabrizio Giordanetto

Volume 2

WILEY-VCH

Volume Editor

Fabrizio Giordanetto

D.E. Shaw Research
Head Medicinal Chemistry
120 W. 45th Street
New York, NY 10036
USA

Series Editors

Prof. Dr. Raimund Mannhold

Rosenweg 7
40489 Düsseldorf
Germany
mannhold@uni-duesseldorf.de

Dr. Helmut Buschmann

RD&C Research, Development &
Consulting GmbH
Ludwigsallee 21
52062 Aachen
Germany
hbuschmann@gmail.com

Dr. Jörg Holenz

Head of Neuroscience Virtual
Proof-of-Concept DPU
R&D Neurosciences TAU
GSK
1250 S. Collegeville Road
Collegeville, PA 19426-0989
USA
joerg.x.holenz@gsk.com

■ All books published by **Wiley-VCH** are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <<http://dnb.d-nb.de>>.

© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form — by photoprinting, microfilm, or any other means — nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Print ISBN: 978-3-527-34149-8

ePDF ISBN: 978-3-527-80176-3

ePub ISBN: 978-3-527-80177-0

Mobi ISBN: 978-3-527-80178-7

oBook ISBN: 978-3-527-80175-6

Cover Design Schulz Grafik-Design,
Fußgönheim, Germany

Typesetting SPi Global Private Limited,
Chennai, India

Printing and Binding

Printed on acid-free paper

Salir all'Infinito

A Michele, per Anna

Contents to Volume 1

Preface *xv*

A Personal Foreword *xix*

- 1 Early Drug Development: Progressing a Candidate Compound to the Clinics** *1*
Fabrizio Giordanetto
References *7*

Part I Drug Substance *9*

- 2 Early Phase API Process Development Overview** *11*
J. Christopher McWilliams and Mark Guinn
- 2.1 Introduction *11*
- 2.2 API Process Development Overview *12*
- 2.2.1 Early Process Development *12*
- 2.2.2 Early Development Drivers and Constraints *12*
- 2.3 The Transition from Discovery to Development *14*
- 2.4 Process Development Organizational Construct *16*
- 2.4.1 Core Functions *16*
- 2.4.2 Specialized Technology Groups *21*
- 2.4.3 Partner Functions *23*
- 2.5 Process Development Equipment *25*
- 2.5.1 Lab Equipment *25*
- 2.5.2 Scale-up Equipment in the Laboratory *26*
- 2.5.3 cGMP Manufacturing Equipment *27*
- 2.6 Summary *28*
References *28*
- 3 The Discovery/Development Transition** *31*
Christopher M. Cimarusti and David R. Kronenthal
- 3.1 Introduction *31*
- 3.2 Discovery-to-development Transition Before 1980 *31*
- 3.2.1 Discovery/Development Handover *33*

3.3	Discovery-to-development Transition in the 1980s	33
3.4	Discovery-to-development Transition in the 1990s	34
3.4.1	Development Time	35
3.4.2	The BMS IND Initiative	36
3.4.2.1	Parallel Activities	37
3.4.2.2	Integration	38
3.4.2.3	Optimization	39
3.4.2.4	Teamwork	40
3.4.2.5	Enthusiasm	40
3.5	Present Practice at BMS	40
3.5.1	The Role of Chemical Complexity	42
3.5.2	An Example of Early Prospective Chemical Development	43
3.6	Application in Small Biotechnology Companies Today	45
3.7	Application in CROs	46
3.7.1	Colocation of CMC Activities	47
3.8	Conclusions	48
	References	48
4	Active Pharmaceutical Ingredient Cost of Goods: Discovery to Early Development	49
	<i>Neal G. Anderson and Todd D. Nelson</i>	
4.1	Introduction	49
4.2	Stages of Research	50
4.3	Synthetic Route Translatability and Scalability: Strategy	51
4.4	Raw Material Considerations	53
4.5	Continual Assessment of Alternative Routes and Technologies, Including Preparative Chromatography	53
4.6	Initial CoG Projections	55
4.7	CoG Versus Campaign Time Cycle	56
4.8	Synthetic Route Translatability and Scalability: Tactics	57
4.9	Preparing a CoG Estimate	59
4.10	Ancillary Expenses	65
4.10.1	Analytical Considerations	65
4.10.2	Polymorph Screening and Salt Screening	65
4.10.3	cGMP Surcharges	66
4.10.4	Critique of the Abilities of Process Groups and Drug Discovery Groups to Advance Development of APIs	66
4.11	Long-Term Considerations	68
4.12	Summary	69
	Acknowledgments	70
	References	70
5	New Technologies in Process Development	73
	<i>Peter W. Sutton, Joseph P. Adams, Charles Wade, and Katherine Wheelhouse</i>	
5.1	Introduction	73
5.2	Synthetic Biochemistry	76
5.2.1	Current State Biocatalysis	78

5.2.2	New Single-step Biotransformations	82
5.2.3	Cascade Biotransformations	86
5.2.4	The Future of Synthetic Biochemistry	89
5.3	Chemical Catalysis	90
5.3.1	Considerations for Application on Process Scale	94
5.3.2	Examples of Recent Catalysis Developments Applied in an Industrial Setting	96
5.3.3	The Future of Chemical Catalysis	101
5.4	Continuous Chemistry	103
5.4.1	Single-stage Continuous Processing	104
5.4.2	Fast Reactions with Unstable Intermediates	104
5.4.3	High Temperature and Pressure	105
5.4.4	Mixing of Biphasic Reactions	106
5.4.5	Safety	106
5.4.6	Photochemistry	107
5.4.7	Electrochemistry	108
5.4.8	Multistage Continuous Processing	109
5.4.9	The Future of Continuous Chemistry	110
5.5	Conclusion	111
	Acknowledgments	113
	References	113

6 Vortioxetine and Early Drug Development Considerations at the Interface of R&D

Morten Jørgensen, Kim Christensen, Martin Juhl, and Benny Bang-Andersen

6.1	Introduction	125
6.2	Synthesis of Vortioxetine	126
6.2.1	Iron-mediated Synthetic Route	128
6.2.2	Mustard Route	129
6.2.3	Palladium-mediated Route	132
6.2.4	Radioligand Synthesis	135
6.3	Metabolites of Vortioxetine	135
6.4	Conclusion	141
	Abbreviations	141
	References	142

7 Development of a Practical Synthesis of 4'-Azido-2' β -Methyl-2'-Desoxycytosine and Its Prodrugs as HCV Chemotherapeutic Agents

Sébastien Lemaire, Tom Govaerts, and Vittorio Farina

7.1	Introduction	145
7.2	New Synthesis of (2' <i>R</i>)-2'-deoxy-2'- <i>C</i> -methyl uridine (10)	149
7.3	Dehydration and Iodoazidation Steps	154
7.4	Functionalization at C-4'	155
7.5	Synthesis of the API	159
7.6	Solid Form Selection	159

7.7	Process Safety	161
7.8	Impurity Strategy	162
7.9	Conclusion	164
	References	164

Part II Drug Product 169

8 Solubility, Permeability, and Their Interplay 171

Avital Beig, Milica Markovic, and Arik Dahan

8.1	Introduction	171
8.2	Solubility	175
8.2.1	Solubility and Dissolution Rate	175
8.2.2	Log <i>P</i>	177
8.2.3	pH	177
8.2.4	Bile Salts	178
8.2.5	The Particle Size	178
8.2.6	Volume of Fluids	179
8.3	Permeability	179
8.3.1	Passive Diffusion	180
8.3.2	Unstirred Water Layer	182
8.3.3	Membrane Transporters	182
8.3.4	P-Glycoprotein (P-gp)	183
8.3.5	MRP2	184
8.3.6	PEPT1	184
8.3.7	OATP	185
8.4	The Solubility–Permeability Interplay	185
8.5	Summary	188
	List of Abbreviations	188
	References	188

9 Solid-State Properties 203

Si-Wei Zhang, Robert F. Dunn, and Alfred Y. Lee

9.1	Introduction	203
9.2	Amorphous and Crystalline States: Basic Concepts	204
9.2.1	Crystalline States: Polymorphs, Hydrates, Solvates, Salts, and Cocrystals	205
9.2.2	Polymorph Screening and the Solid Form Selection Process	206
9.2.2.1	Goal of Form Selection	206
9.2.2.2	Characterization of the Starting Material	208
9.2.2.3	Polymorph Screening Methods	209
9.2.2.4	Assessing the Relative Stability of Multiple Physical Forms	211
9.2.2.5	Form Selection Process	212
9.2.3	Amorphous Solid Dispersions	212
9.2.3.1	Spray Drying	213
9.2.3.2	Hot Melt Extrusion	214
9.2.3.3	Solid Dispersion Workflow	214

9.2.3.4	Dissolution and Stability Issue	214
9.3	Physical Properties of Drug Substance	215
9.3.1	Particle Habit	215
9.3.2	Particle Size	219
9.4	Summary	221
	List of Abbreviations	222
	References	222
10	Salt and Cocrystal Screening	229
	<i>Ann Newman, Cen Chen, and Carlos Sanrame</i>	
10.1	Introduction	229
10.2	Screening	230
10.2.1	Counterions and Coformers	231
10.2.2	Manual Versus Automated Screening	236
10.2.3	Computational Approaches	238
10.2.4	Salt and Cocrystal Screening Strategies	239
10.2.5	Polymorph Screen of Salts/Cocrystals	241
10.3	Salt/Cocrystal Selection	242
10.4	Scale-Up	247
10.5	Formulation Considerations	249
10.6	Regulatory Aspects	255
10.7	Case Studies	257
10.7.1	Indinavir: Early Salt Form Change	257
10.7.2	Atorvastatin: Crystalline Form Change in Late Development	258
10.8	Summary	258
	List of Abbreviations	259
	References	260
11	Particle Size Reduction: From Microsizing to Nanosizing	271
	<i>Dedong Wu and Beth A. Sarsfield</i>	
11.1	Strategic Plans and Risk Management of Particle Size	271
11.2	Particle Size Reduction Techniques	273
11.2.1	Top-Down Approaches	274
11.2.2	Bottom-Up Approaches	275
11.3	Particle Size Analysis	276
11.3.1	Regulatory and Quality Considerations	276
11.3.2	Particle Size Techniques	277
11.3.3	Selection of Appropriate Technique or Set of Techniques	278
11.4	Bioavailability and the Desired Particle Size	290
11.4.1	Particle Size and Bioavailability	290
11.4.2	Initial Desired Particle Size	291
11.5	Enabling Formulation Approach by Particle Size Reduction in Early Drug Development	294
11.6	Benefits of Commercial Products Using Nanosized Crystalline Particles	297

11.7	Perspectives in Nanosizing Crystalline Particles	299
11.7.1	Nanoparticles and Targeting Delivery	299
11.7.2	Emerging Nanoparticle Techniques	300
11.8	Conclusions	301
	References	302
12	Early Drug Development: From a Drug Candidate to the Clinic	305
	<i>Mark McAllister, Joanne Bennett, John Davis, Brian Henry, and Mei Wong</i>	
12.1	Preclinical Formulation Selection	305
12.1.1	Guiding Principles and Technology Selection for Preclinical Formulation	305
12.1.2	Predicting Preclinical Formulation Performance	308
12.2	Formulation Selection for FiH	312
12.2.1	Extemporaneous Preparation	313
12.2.2	Powder in Capsule (PIC) Formulation	313
12.2.2.1	Clinical Performance of PIC Dosage Forms: A Retrospective Data Analysis of Pfizer NCEs	314
12.2.2.2	Clinical Data Analysis Methodology	315
12.2.2.3	Relationship Between Physicochemical Properties and Clinical Performance for PIC Dosage Forms: Results from Clinical Data Analysis	318
12.3	Conclusion	326
	Acknowledgments	327
	References	327
13	A Practical Guide for the Preparation of Drug Nanosuspensions for Preclinical Studies: Including <i>In Vivo</i> Case Studies	333
	<i>Kalle Sigfridsson, Urban Skantze, Pia Skantze, and Lennart Lindfors</i>	
13.1	Introduction	333
13.2	Selecting the Appropriate Type of Formulation Based on Compound Properties and Type of Study	335
13.2.1	Solutions	336
13.2.1.1	pH Adjustment	336
13.2.1.2	Cosolvents	337
13.2.1.3	Solubilization in Cyclodextrins	337
13.2.1.4	Solubilization in Surfactants	337
13.3	Microsuspensions	339
13.4	Nanosuspensions	339
13.4.1	Amorphous or Crystalline Nanosuspension?	339
13.4.2	Selection of Stabilizers	340
13.4.3	Manufacturing Method Selection	341
13.4.3.1	Low API Concentrations (Up to Approximately 10 mM)	341
13.4.3.2	High API Concentrations (Above 10 mM)	342
13.5	Manufacturing Methods	343
13.5.1	Amorphous Nanoparticles at Low Compound Concentrations: The Precipitation Method	343
13.5.2	Amorphous Nanoparticles at High Compound Concentrations: The Melt Emulsion Method	344

- 13.5.3 Crystalline Drug Nanoparticles at Low Compound Concentrations: The Ultrasonic Crystallization Method 346
- 13.5.4 Crystalline Drug Nanoparticles at High Compound Concentrations: The Wet Milling Method 348
- 13.6 Additional Characterizations and Considerations Before *In Vivo* Dose Decisions and Administration Route Selection 350
 - 13.6.1 Solubility Measurements 350
 - 13.6.2 Measurements of Dissolution Rate 351
 - 13.6.3 Colloidal Stability 352
 - 13.6.4 Chemical Stability of the Compound 352
 - 13.6.5 Sterilization Before Parenteral Administration 352
- 13.7 Case Studies 352
 - 13.7.1 Case Study 1: Milled Nanocrystals of a Compound for Toxicological Studies 352
 - 13.7.2 Case Study 2: Amorphous Nanosuspensions Selected for Preclinical and Toxicological Studies Due to Improved Exposure Versus Crystalline Suspensions with Different Particle Sizes 356
 - 13.7.3 Case Study 3: Amorphous Nanoparticles as a Screening Approach During Lead Optimization and in Repeated Toxicological Studies 358
- 13.8 Conclusions 360
 - References 361

Contents to Volume 2

Preface *xix*

A Personal Foreword *xxiii*

Part III Pharmacokinetics and Pharmacodynamics 365

- 14 **Integration of Pharmacokinetic and Pharmacodynamic Reasoning and Its Importance in Drug Discovery 367**
Johan Gabrielsson and Stephan Hjorth
- 15 **Prediction of Human Pharmacokinetics and Pharmacodynamics 399**
Ulf Bredberg
- 16 **Translational Modeling and Simulation for Molecularly Targeted Small Molecule Anticancer Agents: Case Studies of Multiple Tyrosine Kinase Inhibitors, Crizotinib and Lorlatinib 433**
Shinji Yamazaki
- 17 **Informing Decisions in Discovery and Early Development Research Through Quantitative and Translational Modeling 467**
Tjerk Bueters, Christopher R. Gibson, Prajakti A. Kothare, Mallika Lala, Eric M. Parker, Matthew L. Rizk, Daniel Tatosian, Maria E. Trujillo, Pavan Vaddady, and Sandra A.G. Visser

- Part IV Toxicology 497**
- 18 **Preclinical Toxicology Evaluation 499**
Sara Moses, Ulf Andersson, and Martin Billger
- 19 **Nonclinical Safety Pharmacology 527**
Bruce H. Morimoto
- 20 **Early Drug Development 549**
Luis G. Valerio Jr.
- 21 **Addressing Genotoxicity Risk in Lead Optimization: A PDE10A Inhibitor Case Study 581**
Bie M. P. Verbist, Marjolein Crabbe, Freddy Van Goethem, and Hinrich W. H. Göhlmann
- 22 **The Integrated Optimization of Safety and DMPK Properties Enabling Preclinical Development: A Case History with S1P₁ Agonists 603**
Simon Taylor
- 23 **From TRAIL to ONC201: Case Study on the Safety Benefit of Developing Targeted Agents Against Cancer-selective Pathways 631**
Christina Leah B. Kline, Jessica Wagner, Amriti Lulla, Marie D. Ralff, Avital Lev, Lanlan Zhou, Varun V. Prabhu, Martin Stogniew, Lee Schalop, Wolfgang Oster, Joshua E. Allen, and Wafik S. El-Deiry
- Part V Intellectual Property 647**
- 24 **Patent Law Relevant to Early Drug Development 649**
Joanna T. Brougher Esq., MPH and Audrey Ogurchak
- 25 **Patent Protection Strategy 667**
Mark A. Borsos
- 26 **Intellectual Property: The Patent Landscape Viewed from Generic and Originator Perspectives 691**
Jonathan D.M. Atkinson D.Phil; EPA; C Chem. FRSC
- 27 **Patent Considerations in Collaborative Drug Development 721**
MaryAnne Armstrong
- Index 749**

Contents to Volume 1

Preface *xv*

A Personal Foreword *xix*

- 1 **Early Drug Development: Progressing a Candidate Compound to the Clinics** *1*
Fabrizio Giordanetto
References *7*

- Part I **Drug Substance** *9*

- 2 **Early Phase API Process Development Overview** *11*
J. Christopher McWilliams and Mark Guinn

- 3 **The Discovery/Development Transition** *31*
Christopher M. Cimarusti and David R. Kronenthal

- 4 **Active Pharmaceutical Ingredient Cost of Goods: Discovery to Early Development** *49*
Neal G. Anderson and Todd D. Nelson

- 5 **New Technologies in Process Development** *73*
Peter W. Sutton, Joseph P. Adams, Charles Wade, and Katherine Wheelhouse

- 6 **Vortioxetine and Early Drug Development Considerations at the Interface of R&D** *125*
Morten Jørgensen, Kim Christensen, Martin Juhl, and Benny Bang-Andersen

- 7 **Development of a Practical Synthesis of 4'-Azido-2'β-Methyl-2'-Desoxycytosine and Its Prodrugs as HCV Chemotherapeutic Agents** *145*
Sébastien Lemaire, Tom Govaerts, and Vittorio Farina

- Part II Drug Product 169**
- 8 Solubility, Permeability, and Their Interplay 171**
Avital Beig, Milica Markovic, and Arik Dahan
- 9 Solid-State Properties 203**
Si-Wei Zhang, Robert F. Dunn, and Alfred Y. Lee
- 10 Salt and Cocrystal Screening 229**
Ann Newman, Cen Chen, and Carlos Sanrame
- 11 Particle Size Reduction: From Microsizing to Nanosizing 271**
Dedong Wu and Beth A. Sarsfield
- 12 Early Drug Development: From a Drug Candidate to the Clinic 305**
Mark McAllister, Joanne Bennett, John Davis, Brian Henry, and Mei Wong
- 13 A Practical Guide for the Preparation of Drug Nanosuspensions for Preclinical Studies: Including *In Vivo* Case Studies 333**
Kalle Sigfridsson, Urban Skantze, Pia Skantze, and Lennart Lindfors

Contents to Volume 2

Preface *xix*

A Personal Foreword *xxiii*

- Part III Pharmacokinetics and Pharmacodynamics 365**
- 14 Integration of Pharmacokinetic and Pharmacodynamic Reasoning and Its Importance in Drug Discovery 367**
Johan Gabrielsson and Stephan Hjorth
- 14.1 Introduction 367
- 14.2 Understand Your Target Biology 369
- 14.2.1 Physiological Context 371
- 14.2.2 Which Biomarker to Monitor 372
- 14.2.3 Buffering, Tolerance, and Redundancy in Targeted Functions 372
- 14.2.4 Target vs Off-Target or Confounding Factors 372
- 14.2.5 Experimental Model and Protocol 373
- 14.2.6 Experimental Design Aiming at Target Biology 373
- 14.2.7 Species and Translation 374
- 14.2.8 Treatment vs Cure 374
- 14.3 Understand Your Concentration–Response Relationship and Time Delays 374
- 14.3.1 Nonmonotonous Concentration–Response Curves 375
- 14.3.2 Dose Scheduling (“Dose Fractioning”) 377
- 14.3.3 What Matters Is Steady State for Chronic Indications 378
- 14.4 Understand Temporal Differences Between Concentration and Response 382

14.4.1	Models of Time Delays	385
14.5	Understand Your Translational Context and Options	385
14.5.1	Matching Drug Delivery to Target Biology	385
14.5.2	Designing Experiments for Discrimination of Drug Candidates	387
14.5.3	A Model for Differentiation of System and Drug Properties	389
14.6	Communication Across Discovery Disciplines	389
14.6.1	Misconceptions in Cross-Functional Communication	389
14.6.2	The <i>In Vitro</i> vs <i>In Vivo</i> Perspective	392
14.6.3	Integrated Thinking	392
14.7	Final Remarks	395
	References	396
15	Prediction of Human Pharmacokinetics and Pharmacodynamics	399
	<i>Ulf Bredberg</i>	
15.1	General Introduction	399
15.1.1	PK, PKPD, and Dose Prediction: Overview	400
15.2	Predicting Human Pharmacokinetics	401
15.2.1	Experimental Data	401
15.2.2	Predicting Clearance	402
15.2.2.1	Hepatic Metabolic Clearance	403
15.2.2.2	Hepatic Biliary Clearance	406
15.2.2.3	Renal Clearance	407
15.2.2.4	Scaling of Clearance: Points to Consider	408
15.2.3	Volume of Distribution	410
15.2.4	Oral Bioavailability, Rate, and Extent of Absorption	412
15.2.4.1	Extent of Absorption and Gut First-Pass Metabolism	413
15.2.4.2	Rate of Absorption	414
15.2.4.3	Prediction of Bioavailability and Absorption: Points to Consider	414
15.2.5	Predicting PK Profiles	414
15.2.5.1	One-compartment Model Predictions	415
15.2.5.2	PBPK Models	415
15.2.5.3	PK Predictions for the Target Patient Population	416
15.3	Predicting Human PKPD	416
15.3.1	Introduction	416
15.3.2	Fundamental Principles for Successful PKPD Prediction and Translation	416
15.3.2.1	Target Modulation/Engagement and the Pharmacologic Effect	418
15.3.2.2	Relationship Between Pharmacokinetics and Target Engagement/Modulation	419
15.3.2.3	Analyses of PKPD Data	421
15.3.2.4	Predicting Efficacious Concentration Without a Target Engagement or Mechanistic Biomarker	421
15.3.2.5	Translating from Preclinical PKPD to Human PKPD: Points to Consider	422
15.4	Dose Predictions	422
15.5	Estimating and Conveying Uncertainty in PK and PKPD Predictions	425
15.6	Future Perspectives	425
	References	426

- 16 Translational Modeling and Simulation for Molecularly Targeted Small Molecule Anticancer Agents: Case Studies of Multiple Tyrosine Kinase Inhibitors, Crizotinib and Lorlatinib 433**
Shinji Yamazaki
- 16.1 Introduction 433
- 16.2 Translational Pharmacology in Oncology 434
- 16.3 Quantitative M&S Approach 436
- 16.3.1 PK Modeling 437
- 16.3.2 PKPD Modeling 438
- 16.3.3 PKDZ Modeling 440
- 16.4 Case Study: Crizotinib (PF02341066) 441
- 16.4.1 Nonclinical Study Outlines 442
- 16.4.2 PK Analysis 443
- 16.4.3 PKPD Relationships 444
- 16.4.4 PKDZ Relationships 446
- 16.4.5 PK–PDDZ Understanding 446
- 16.4.6 Translational Pharmacology 449
- 16.5 Case Study: Lorlatinib (PF06463922) 451
- 16.5.1 Nonclinical Study Outlines 452
- 16.5.2 PK Analysis 452
- 16.5.3 PKPD Relationships 453
- 16.5.4 PKDZ Relationships 454
- 16.5.5 PK–PDDZ Understanding 456
- 16.5.6 Translational Pharmacology 457
- 16.6 Closing Remarks 459
- Acknowledgment 460
- List of Abbreviations 460
- References 461
-
- 17 Informing Decisions in Discovery and Early Development Research Through Quantitative and Translational Modeling 467**
Tjerk Bueters, Christopher R. Gibson, Prajakti A. Kothare, Mallika Lala, Eric M. Parker, Matthew L. Rizk, Daniel Tatosian, Maria E. Trujillo, Pavan Vaddady, and Sandra A.G. Visser
- 17.1 Introduction 467
- 17.1.1 Translational Plan 470
- 17.2 Neuroscience: Prediction of the Clinically Efficacious Exposure and Dose Regimen for a Novel Target 472
- 17.3 Diabetes: Leveraging a Platform Approach for Two-way Translation and Integration of Knowledge Between Clinical Lead and Backup Discovery Compounds 476
- 17.3.1 Evolution of Pharmacology Experiments 476
- 17.3.2 Development of a Translational PK/PD Model 479

- 17.3.3 Application of the GPR40 Agonist Translational PK/PD Model to Establish IVIVC 480
- 17.3.4 Application of the GPR40 Agonist Translational PK/PD Model to Predict Clinical Outcomes 480
- 17.4 Antibacterials: Semi-mechanistic Translational PK/PD Approach to Inform Optimal Dose Selection in Human Clinical Trials for Drug Combinations 483
 - 17.4.1 Development of the Semi-mechanistic Translational PK/PD Model 484
 - 17.4.2 Application of the Translational PK/PD Model to Predict Preclinical Efficacy 486
 - 17.4.3 Application of the Translational PK/PD Model to Predict Clinical Efficacy 487
- 17.5 Anti-inflammation: Early Go/No-Go Based on Differentiation Potential Compared with Competitors 489
- 17.6 Summary 491
 - List of Abbreviations 493
 - References 494

Part IV Toxicology 497

- 18 Preclinical Toxicology Evaluation 499**
Sara Moses, Ulf Andersson, and Martin Billger
 - 18.1 Introduction 499
 - 18.1.1 Target Safety Assessment 500
 - 18.1.2 Compound Safety Assessment 504
 - 18.1.2.1 Cytotoxicity 505
 - 18.1.2.2 Mitochondrial Toxicity 505
 - 18.1.2.3 Biotransformation and Reactive Metabolites 506
 - 18.1.2.4 Secondary Pharmacology 507
 - 18.1.2.5 Phototoxicity 508
 - 18.1.2.6 Genetic Toxicology 509
 - 18.1.2.7 Genotoxic Impurities 510
 - 18.1.2.8 Incorporation of Safety Endpoints in Preclinical Efficacy and PK Studies 511
 - 18.1.2.9 Safety Pharmacology 512
 - 18.1.2.10 Maximum Tolerated Dose (MTD) / Dose Range Finding (DRF) Studies 512
 - 18.1.3 GLP Toxicology 513
 - 18.1.3.1 General Toxicology 515
 - 18.1.4 Enabling the First Clinical Trial with Toxicological Data 516
 - 18.1.5 Toxicology Studies Beyond Phase I Clinical Trials 517
 - 18.2 Conclusions 517
 - List of Abbreviations 519
 - References 519

19	Nonclinical Safety Pharmacology	527
	<i>Bruce H. Morimoto</i>	
19.1	Introduction	527
19.2	Historical Background	528
19.3	Regulatory Framework	529
19.4	Role in Discovery and Candidate Selection	530
19.5	Preparation for First-in-human Studies	532
19.5.1	Introduction	532
19.5.2	Objectives	533
19.5.3	General Principles	534
19.5.4	Central Nervous System	534
19.5.5	Cardiovascular System	536
19.5.5.1	Chemical or Pharmacological Class	538
19.5.5.2	<i>In Vitro</i> Evaluation of I_{kr} (hERG) Inhibition	538
19.5.5.3	Cardiac Action Potential	538
19.5.5.4	<i>In Vivo</i> Assessments	539
19.5.6	Respiratory System	540
19.5.7	Supplemental Safety Pharmacology Studies	540
19.5.7.1	Renal Safety Pharmacology	541
19.5.7.2	Gastrointestinal System	541
19.6	Translation from Nonclinical Safety Pharmacology to the Clinic	541
19.7	Future Directions and Current Discussions	543
19.8	Summary	544
	List of Abbreviations	544
	References	545
20	Early Drug Development	549
	<i>Luis G. Valerio Jr.</i>	
20.1	Introduction	549
20.2	Predictive Toxicology	550
20.3	Predictive Modeling	552
20.3.1	Machine Learning Algorithms	552
20.3.1.1	Decision Trees	553
20.3.1.2	Ensembles of Models	553
20.3.1.3	k -Nearest Neighbors	555
20.3.1.4	Naïve Bayes Classifiers	556
20.3.1.5	Artificial Neural Networks	556
20.3.2	Knowledge-based Methods	557
20.4	Industry Perspectives	558
20.5	Regulatory Perspectives	567
20.6	Conclusion	570
	List of Abbreviations	572
	References	572

21	Addressing Genotoxicity Risk in Lead Optimization: A PDE10A Inhibitor Case Study 581
	<i>Bie M. P. Verbist, Marjolein Crabbe, Freddy Van Goethem, and Hinrich W. H. Göhlmann</i>
21.1	Introduction 581
21.2	Lead Optimization Project: Searching for PDE10A Inhibitors 583
21.3	Transcriptional Profiling to Capture Polypharmacology 583
21.4	High Content Imaging as an Independent Confirmation 585
21.5	<i>In Vitro</i> Micronucleus Testing to Validate Transcriptional Signature 589
21.6	Data Integration 591
21.7	Hypothesis for a Potential Structure–Activity Relationship 592
21.8	Conclusion 594
21.8.1	Current Situation 594
21.8.2	Suggested Improvements 595
21.8.3	Expected Outcome 596
21.8.4	Future Opportunities 598
	List of Abbreviations 598
	References 599
22	The Integrated Optimization of Safety and DMPK Properties Enabling Preclinical Development: A Case History with S1P₁ Agonists 603
	<i>Simon Taylor</i>
22.1	Introduction to the S1P ₁ Agonist Lead Optimization Program 603
22.1.1	Objectives and Challenges 603
22.1.2	Overview of the Strategy and Screening Cascade 604
22.2	Early Attention to Preclinical Safety 605
22.2.1	Use of Toxicogenomics in Early Rodent Safety Studies 607
22.3	Aryl Hydrocarbon Receptor Activation Observed in Rat 607
22.4	CYP1A (Auto) Induction Observed in Non-rodent Species 609
22.5	Introduction to the Biology and Function of the Aryl Hydrocarbon Receptor 611
22.5.1	CYP1A Induction via the AhR 611
22.5.2	<i>CYP1A Enzyme Family</i> 612
22.6	Considerations of AhR Binding and CYP1A Induction on Compound Progression 613
22.7	Reacting to Data: Strategy Modification in Lead Optimization 615
22.7.1	Evaluating CYP1A Induction in Human Systems 615
22.7.2	Evaluating Induction in Human Hepatocytes 615
22.7.3	Screening for Induction Using Rat Hepatocytes 617
22.7.4	Development of a Rat <i>In Vivo</i> Induction Protocol 618
22.8	Iterative Experimentation Identifies Molecules for Progression 619

22.9	Delivery of Human AhR Agonist Assay	622
22.10	Minimizing Cardiovascular Safety Risk Through S1P Receptor Selectivity	623
22.11	Positioning Dose as the Focus of Lead Optimization	625
22.12	Delivery of Multiple Candidates for Development	625
22.13	Conclusions	626
	Acknowledgments	627
	References	627
23	From TRAIL to ONC201: Case Study on the Safety Benefit of Developing Targeted Agents Against Cancer-selective Pathways	631
	<i>Christina Leah B. Kline, Jessica Wagner, Amriti Lulla, Marie D. Ralff, Avital Lev, Lanlan Zhou, Varun V. Prabhu, Martin Stogniew, Lee Schalop, Wolfgang Oster, Joshua E. Allen, and Wafik S. El-Deiry</i>	
23.1	Introduction: Toxicity, a Reason Behind Failed Clinical Trials	631
23.2	Addressing Safety at the Onset: Targeting a Cancer-specific Pathway	631
23.2.1	Choosing to Activate the TRAIL Pathway as a Cancer Therapeutic Strategy	631
23.2.2	Mechanisms Behind Cancer Selectivity	633
23.2.3	Strategies of TRAIL Pathway Therapeutic Engagement	633
23.2.3.1	Using TRAIL	633
23.2.3.2	Using Antibodies Against TRAIL Receptors	634
23.2.3.3	Using Small Molecules to Activate the TRAIL Pathway	634
23.3	Maximizing Efficacy and Minimizing Toxicity at the Bench	635
23.3.1	Decision making: Choice of Which Compound to Move Forward with (Comparison of the Different TICs) – Balancing Efficacy with Safety	635
23.3.2	Expanded <i>In Vitro</i> Evaluation of Efficacy and Safety	636
23.3.3	Exploring Therapeutic Potential by Performing <i>Ex Vivo</i> Studies	636
23.4	Leveraging Preclinical Animal Studies to Predict Clinical Performance	637
23.4.1	Identifying Vulnerable Tumor Types	637
23.4.2	Assessing Impact on Normal Tissue	637
23.4.2.1	Classical Indicators of Toxicity	637
23.4.2.2	Pharmacodynamic Analyses	637
23.4.3	Conducting Toxicology Studies in Accordance with Good Laboratory Practices (GLP)	638
23.5	Applying Lessons from <i>In Vitro</i> and <i>In Vivo</i> Studies to Clinical Trials	639
23.6	Summary	639
	References	640

Part V Intellectual Property 647

- 24 Patent Law Relevant to Early Drug Development 649**
Joanna T. Brougher Esq., MPH and Audrey Ogurchak
- 24.1 Introduction 649
 - 24.2 Overview of Patent Protection 649
 - 24.2.1 What Are Patents? 649
 - 24.2.2 What Is the Purpose of a Patent? 650
 - 24.2.3 Types of Patents 650
 - 24.2.4 Patent Term and Scope 651
 - 24.3 Requirements for Patent Protection 651
 - 24.3.1 Eligible Subject Matter 652
 - 24.3.2 Utility 652
 - 24.3.3 Novelty 653
 - 24.3.4 Nonobviousness 653
 - 24.3.5 Enablement 654
 - 24.4 Patent Infringement 654
 - 24.5 Overview of Drug Development 656
 - 24.6 Extending the Life of a Product 658
 - 24.6.1 Hatch–Waxman Act 658
 - 24.6.2 Patent Exclusivities 659
 - 24.6.2.1 Delays Due to USPTO Approval 659
 - 24.6.2.2 Delays Due to Regulatory Approval 660
 - 24.6.3 Non-patent Exclusivities 660
 - 24.6.3.1 New Chemical Entity 660
 - 24.6.3.2 New Clinical Study Exclusivity 661
 - 24.6.3.3 Generic Drugs 662
 - 24.6.3.4 Orphan Drug Exclusivity 663
 - 24.6.3.5 Pediatric 664
 - 24.7 Summary 665
 - References 666
- 25 Patent Protection Strategy 667**
Mark A. Borsos
- 25.1 Benefits of Patent Protection 667
 - 25.2 Requirements for Patentability 668
 - 25.2.1 Subject Matter Eligible for Patent Protection 668
 - 25.2.2 Further Requirements for Patentability: Defining the Invention 669
 - 25.3 The Significance of a Patent Portfolio 671
 - 25.3.1 Protection of Commercial Products and Exclusive Rights 671
 - 25.3.2 Monetization of Patents 672
 - 25.4 Planning a Patent Portfolio 673
 - 25.4.1 First- Versus Second-Generation Drugs 673
 - 25.4.2 Active Pharmaceutical Ingredient 674

25.4.3	Formulations	675
25.4.4	Dosages, Administration Forms, and Treatment Methods	676
25.4.5	Methods of Manufacture	677
25.4.6	Anticipating Further Development and Variation	677
25.4.7	Designing Around Prior Art	678
25.5	Timing of Patent Applications	678
25.5.1	Provisional and Nonprovisional Patent Applications	679
25.5.2	Patent Cooperation Treaty Applications and International Filings	679
25.5.3	Factoring in Continued Development of Drug Formulations	680
25.5.4	Accounting for Publication or Presentation of Research	680
25.6	Prosecution of Patent Applications	681
25.6.1	Defining Inventions in View of the Prior Art	681
25.6.2	The Meaning of Patent Claims: Proactive Claim Construction	681
25.6.3	The Importance of the Patent Specification	682
25.6.4	Amendments and Arguments	683
25.6.5	Anticipating Challenges to Infringement and Validity	683
25.7	Extending Patent Coverage Through Additional Applications	684
25.7.1	Continuation Applications	684
25.7.2	Continuation-in-Part Applications	684
25.7.3	Divisional Applications	685
25.8	Modifications to Issued Patents	686
25.8.1	Correcting Issued Patents Through Reissue	686
25.8.2	Limitations on Broadening Claims	687
25.8.3	Limitations on Damages	688
25.9	Conclusion	688
26	Intellectual Property: The Patent Landscape Viewed from Generic and Originator Perspectives	691
	<i>Jonathan D.M. Atkinson D.Phil; EPA; C Chem. FRSC</i>	
26.1	Introduction	691
26.2	Market Exclusivities That Protect Branded Drugs	691
26.3	The Patent Cliff	695
26.4	Paragraph IV Issues	697
26.5	Injunctions	699
26.6	The Generic Company's Goals	703
26.7	Strategies Adopted by Innovators	704
26.8	Strategies Adopted by Generic Companies	712
26.9	Conclusion	718
27	Patent Considerations in Collaborative Drug Development	721
	<i>MaryAnne Armstrong</i>	
27.1	Introduction	721
27.2	What is Intellectual Property?	722
27.2.1	Patents	722
27.2.2	Trade Secrets	724

27.2.3	Trademark and Copyright	724
27.3	Before the Research Begins	725
27.3.1	Nondisclosure Agreements (NDAs)	727
27.3.2	Is a Freedom to Operate Search Needed?	727
27.3.3	Scope of the Collaboration	728
27.3.4	Trade Secrets	729
27.3.5	Procedures for Making Public Announcements and Publications	730
27.3.6	Ownership	732
27.3.7	Dealing with Problems	735
27.3.8	Costs	736
27.3.8.1	Prosecution Costs	737
27.3.8.2	Enforcement Costs	738
27.3.9	Indemnifications	739
27.3.10	Sharing Technology	739
27.4	After the Research Ends and the Patent Issues	742
27.4.1	Litigations	742
27.4.1.1	Required Participation in a Litigation	742
27.4.1.2	Who Will Enforce the Patents?	744
27.4.2	Patent Term Extension	744
27.5	Termination of the Relationship (Death and Divorce)	745
27.6	Conclusion	746
	List of Abbreviations	746
	References	747

Index	749
--------------	------------

Preface

Modern research in drug discovery and development (DDD) resulted in enormous progress in understanding disease-underlying mechanisms on a molecular level via systems biology strategies and in developing advanced methodological tools [1]. Regrettably, however, this progress did not translate into higher rates of successful approvals for new chemical entities (NCEs). Only one out of 5000–10 000 NCEs is approved, and only one out of nine compounds in clinical development reaches the market [1].

To counteract this unsatisfactory situation and to reduce the number of late-stage failures of clinical candidates, current pharma research dedicates an increased attention to a particular step in the DDD path: the early or preclinical drug development step [1–3] that comprises all activities aimed at bringing optimized lead structures to first-in-human trials considering pharmacological and toxicological characterization as well as GLP and GMP activities according to regulatory guidelines. The goal is to optimally filter out “detrimental” compounds at a very early state of the process and thereby to increase success rates.

In the introduction of this book, Fabrizio Giordanetto gives an overview of the general early drug development (early DD) workflow. In four follow-up sections, the sequential steps of early DD are described in detail, focusing on the availability of the drug substance according to GMP guidelines and the solid phase characterization, the availability of the drug product after preformulation work, the prediction of PK/PD, and the *in silico*, *in vitro*, and *in vivo* prediction of drug safety. All sections include several case studies to further exemplify the respective early DD steps under consideration. Finally, strategic aspects of patenting are addressed.

Drug substance: Drug substance is defined as an active ingredient intended to furnish pharmacologic activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the body; it does not include intermediates used in the synthesis of such an ingredient. Chapters in this section particularly concern process chemistry including route-finding and up-scaling environmental aspects such as green chemistry and costs of goods.

Drug product: The drug product is defined as the finished dosage form, often comprising the drug substance formulated with inactive ingredients optimized for the intended application route with a suitable ADME profile. Drug formulation and their delivery into the human body represent a central